Mark S. Livingston, an officer at Progyny, Inc., has filed to sell 2,139 shares of the company. This transaction comes after a series of stock vesting events and highlights Livingston's personal financial management strategy. The filing is significant as it may influence investor perceptions of executive actions within the health services sector.

Background

Progyny, Inc. is a company classified under the SIC code for Services-Misc Health & Allied Services, NEC. The firm is incorporated in Delaware and has its business address at 1359 Broadway, 2nd Floor, New York, NY. The company is publicly traded on the NASDAQ under the SEC file number 001-39100. Recent filings show that Livingston has been actively managing his stock holdings, with multiple transactions occurring in the past few months.

What the Filing Says

The filing, dated November 4, 2026, reveals that Livingston plans to sell the shares at an aggregate market value of $64,170. The shares were acquired through restricted stock vesting on September 2, September 3, and September 4 of this year. The nature of these transactions is linked to compensation, indicating that the shares were part of Livingston's remuneration package.

Impact

This filing may affect Progyny's investor relations, as executive stock sales can sometimes raise questions about confidence in the company's future. Additionally, it reflects broader trends in the health services industry, where executives often liquidate shares post-vesting to manage personal finances. Competitors in the sector may observe these actions closely to gauge market sentiment and executive confidence.

What's Next

The filing does not say what happens next regarding further transactions or any potential impacts on Progyny's stock performance.